Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336831 | 0.82 | MAPT (0.50) | TSHRRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6571065 | 0.82 | CA1 (0.38) | TSHRKMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3932697 | 0.77 | TDP1 (0.44) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL97370 | 0.76 | CA1 (0.62) | TSHRKMT2ASMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL1111410 | 0.76 | TSHR (0.44) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8975558 | 0.76 | TSHR (0.43) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL9281834 | 0.74 | TSHR (0.42) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2501881 | 0.74 | KDM4E (0.38) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2495997 | 0.74 | CYP1A2 (0.52) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2095272 | 0.73 | ALDH1A1 (0.42) | TSHRKMT2ASMN1; SMN2ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
| WO-2003024451-A1 | 2-(2-PHENYLETHYL)-BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | claimed |
| EP-0741741-B1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 2002-08-28 | — | — | EP | claimed |
| US-6066447-A | INCLUDING NUCLEOSIDE DIMERS WITH MODIFIED BACKBONES; FOR VIRICIDES AND ANTISENSE AGENTS | NOVARTIS CORPORATION (US) | 2000-05-23 | — | — | US | claimed |
| WO-1998000434-A1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 1998-01-08 | — | — | WO | claimed |
| US-5610300-A | ANTIVIRAL, ANTIPROLIFERATIVE, ANTISENSE TECHNOLOGY, DIAGNOSIS | CIBA-GEIGY CORPORATION (US) | 1997-03-11 | — | — | US | claimed |
| EP-0741741-A1 | MODIFIED OLIGONUCLEOTIDES | Novartis AG (CH) | 1996-11-13 | — | — | EP | claimed |
| US-5461152-A | Nucleoside intermediates for antisense oligonucleotides, antiviral agents | CIBA-GEIGY CORPORATION (US) | 1995-10-24 | — | — | US | claimed |
| WO-1995020597-A1 | MODIFIED OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1995-08-03 | — | — | WO | claimed |
| US-5393878-A | Pyrimidine nucleosides having cyclopentafuran skeleton | CIBA-GEIGY CORPORATION (US) | 1995-02-28 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| EP-0331593-B1 | PROCESS FOR THE PREPARATION OF HYDROXYBENZALDEHYDES BY HYDROCARBONYLATION | RHONE-POULENC CHIMIE (FR) | 1992-11-25 | — | — | EP | claimed |
| EP-0351336-B1 | PROCESS FOR THE PREPARATION OF HYDROXYBENZALDEHYDES BY HYDROCARBONYLATION | RHONE-POULENC CHIMIE (FR) | 1992-10-28 | — | — | EP | claimed |
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | claimed |
| US-4933497-A | Preparation of hydroxybenzaldehydes by hydrocarbonylation of halophenols | RHONE-POULENC CHIMIE (FR) | 1990-06-12 | — | — | US | claimed |
| EP-0351336-A1 | Process for the preparation of hydroxybenzaldehydes by hydrocarbonylation | RHONE-POULENC CHIMIE (FR) | 1990-01-17 | — | — | EP | claimed |
| EP-0331593-A1 | Process for the preparation of hydroxybenzaldehydes by hydrocarbonylation | RHONE-POULENC CHIMIE (FR) | 1989-09-06 | — | — | EP | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | TPSAB1, PRSS3, TPSD1 | TSHR 969/4885NPC1 3164/4885RAB9A 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.